Tag Archives: Boston Biotech Watch
How I stopped worrying and learned to love Twitter: Top Hundred Life Sciences Twitterers to Follow
Twitter last month hit a half-billion users and no wonder. What a valuable business tool!. Adoption is accelerating in the biotech world. Initially I was skeptical – “What, me ‘tweet?’ You’ve got to be kidding!” But now I’m a believer. Here, I share some of Twitter’s benefits, giving readers a quick way to increase the value they can derive from Twitter. Continue reading
Filed under Uncategorized
“Quant” VC Correlation Ventures: VC’s New “Dream Date”
Those venture capitalists lucky enough to remain in the drastically smaller pack are constantly cruising for the perfect co-investor. Like the perfect spouse, it’s hard to imagine finding it all in one person: Quick decision. Even if it is a … Continue reading
Filed under Uncategorized
Partnering360: A New Social Network Aims At Biotech – And Succeeds
We recently test-drove Partnering360, a new social network for biotech and pharma executives that meets a real need. Here we give details on what makes us think this network will succeed and describe some of the challenges to its growth. Continue reading
Filed under Uncategorized
How Sanofi Could Start Off on the Right Foot in Cambridge
Now that the Sanofi acquisition of Genzyme is nearly done – the New York Times is reporting that it may well be announced before the Sanofi board meeting on Wednesday – we look to the aftermath. Instead of just laying off the entire R&D team – which until recently accounted for $800 million in annual spending – why not set up a corporate venture fund to save at least part of the talent base and build an even bigger bridge to the Boston biotech community?
Read the post and comment on my suggestion on Xconomy here or copy-paste the link:
http://www.xconomy.com/boston/2011/02/07/how-sanofi-could-start-off-on-the-right-foot-in-cambridge/?single_page=true
Continue reading
Filed under Uncategorized
We are our bugs – hot Boston startup mines the gut
The next Boston-area startup takes on our dual nature as “higher” eukaryotes who are in fact stuffed full of bacteria – which could be tweaked or targeted to improve our health. Continue reading
Filed under Uncategorized
Company Serves New Genetic Testing Market: The Not-Yet-Conceived
By Steve Dickman, CEO, CBT Advisors What’s the next key population for personalized medicine? We’ve got it: not those with hereditary disease nor those with chronic conditions. Not even anyone who is sick, well, young or old. It’s the not-yet-conceived. … Continue reading
Filed under Uncategorized
Domain Sheds the VC Blues
by Steven Dickman, CEO, CBT Advisors Looking for a silver lining in the current challenging climate for healthcare VC? Look no further than Domain Associates. Amid the exit drought brought on by the economic crisis, Domain has put together an … Continue reading
Filed under Uncategorized
Networking Your Medication
Some iPhone apps have shown that mobile phones are potentially fantastic tools for one-way or two-way transmission of medical information. But actual digital pills!!?? Sure enough: at last week’s JP Morgan healthcare conference, Novartis announced a $24 million deal with Proteus Biomedical, a Bay Area, VC- and private-equity-backed maker of “smart pills” carrying embedded sensors that transmit their status (“Patient just ingested me”) to a phone and then to medical professionals via a wireless network. Boston Biotech Watch has the story. Continue reading
Filed under Uncategorized
Medicine Gets Personal – But How Do VCs Make Money?
Venture investors are warming to the idea of doing deals in “personalized medicine” – diagnostic tests, often based on genetics, that could improve outcomes and lower costs. But regulatory and reimbursement hurdles are the norm, not the exception. Nonetheless, some deals such as Highland Capital’s portfolio company Generation Health, appear very attractive. Continue reading
Filed under Uncategorized
